879 results on '"Flipo, René-Marc"'
Search Results
52. Increased mortality in patients with RA-associated interstitial lung disease: data from a French administrative healthcare database.
53. Évaluation de l’adhésion médicamenteuse dans la polyarthrite rhumatoïde : Compliance Questionnaire of Rheumatology versus Morisky-Green ?
54. NSAID Exposure Delays Time-to-Conception in Patients with Spondyloarthritis: An Analysis of the GR2 Prospective Cohort
55. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment
56. Abatacept Monotherapy Versus Abatacept Plus Methotrexate for Treatment-Refractory Rheumatoid Arthritis
57. Prevalence and predictors of atlanto-axial subluxation in rheumatoid arthritis after 12-years' follow-up (ESPOIR Cohort).
58. Therapeutic consequences in patients with both inflammatory rheumatic diseases and multiple sclerosis.
59. Réponse au traitement, maintien thérapeutique et tolérance des anti-tumour necrosis factor α chez 193 patients atteints de rhumatisme psoriasique : une expérience de 12 ans dans la « vraie vie »
60. Treatment response, drug survival and safety of anti-tumour necrosis factor α therapy in 193 patients with psoriatic arthritis: A twelve-year “real life” experience
61. Characteristics of Patients Treated with JAK Inhibitors in Rheumatoid Arthritis before versus after VTE Risk Warnings
62. L’amélioration des paramètres rapportés par les patients atteints de polyarthrite rhumatoïde traités par sarilumab est indépendante des niveaux cognitifs
63. Persistance des traitements anti-TNFα et anti-IL17 dans la spondyloarthrite axiale : résultats d’une étude observationnelle multicentrique
64. Characterisation of a high-risk profile for maternal thrombotic and severe haemorrhagic complications in pregnant women with antiphospholipid syndrome in France (GR2): a multicentre, prospective, observational study
65. Frequency and determinants of surgical treatment in patients with uncomplicated disc-related sciatica hospitalized in the Rheumatology Department of Lille University Hospital
66. Therapeutic consequences in patients with both inflammatory rheumatic diseases and multiple sclerosis
67. Prevalence and predictors of atlanto-axial subluxation in rheumatoid arthritis after 12-years’ follow-up (ESPOIR Cohort)
68. Treatment persistence of tumour necrosis factors and IL-17 inhibitors in axial spondyloarthritis: A multi-center comparative analysis
69. Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study
70. A Risk Score to Detect Subclinical Rheumatoid Arthritis–Associated Interstitial Lung Disease
71. COVID-19 outcomes in giant cell arteritis and polymyalgia rheumatica versus rheumatoid arthritis: A national, multicenter, cohort study
72. Improvement in patient-reported outcomes in rheumatoid arthritis patients treated with sarilumab is independent of the cognition levels
73. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study
74. Noninfectious Arthritis
75. Taux de rétention de l’adalimumab, de l’étanercept et de l’infliximab en 1re ou 2e ligne de biothérapie chez les patients atteints de polyarthrite rhumatoïde en pratique courante
76. Pregnancy and neonatal outcomes in women with axial spondyloarthritis: pooled data analysis from the European Network of Pregnancy Registries in Rheumatology (EuNeP)
77. Serum Fatty Acid Profiles Are Associated with Disease Activity in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort
78. Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016–2017
79. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice
80. Étude des hospitalisations pour goutte dans un service de rhumatologie entre 2000 et 2010 – Analyse rétrospective de 114 observations
81. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study
82. Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort
83. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE
84. Changes in the incidence and management of spinal tuberculosis in a French University Hospital Rheumatology Department from 1966 to 2010
85. Évolution des prescriptions de biosimilaires d’étanercept et d’adalimumab en initiation dans la polyarthrite rhumatoïde en France : données du registre ART-SFR
86. Impact of Axial Spondyloarthritis on Quality of Life: Results From the European Map of Axial Spondyloarthritis (EMAS) Study in France
87. Assessment of the effect of Tofacitinib on bone marrow adipocytes and bone-forming osteoblasts under non-inflammatory and inflammatory conditions
88. Évolution de l’incidence et de la prise en charge de la tuberculose vertébrale au sein d’un service universitaire français de rhumatologie, de 1966 à 2010
89. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study
90. Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry
91. Additional file 16 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis
92. Additional file 4 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis
93. Additional file 6 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis
94. Additional file 5 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis
95. Additional file 9 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis
96. Additional file 2 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis
97. Additional file 3 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis
98. Additional file 7 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis
99. Additional file 8 of Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis
100. Bilateral fractures of the scapula: Possible archeological examples of beatings from Europe, Africa and America
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.